Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Minimal residual disease (MRD) testing has become a central response biomarker in clinical trials of time-limited treatment, with MRD-guided strategies under increasing evaluation. This article compares key technical and practical features of available MRD approaches and provides guidance on selecting the appropriate method and threshold for varied clinical applications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hoc.2025.05.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: The residual risk of chronic kidney disease (CKD) progression remains high in clinical trials of kidney protective drugs in patients with diabetic kidney disease (DKD).
Methods: In a prospective study, we assessed whether 16 plasma and 10 urine cytokine levels can inform the residual risk of CKD progression in 93 incident patients with DKD treated by Nephrology according to clinical guidelines.
Results: Plasma and urine levels of 12 plasma and 7 urinary cytokines differed between patients with DKD and from healthy controls.
Primary Cutaneous CD4+ Small Medium T Cell Lymphoproliferative Disorder - 20 years of experience from a specialist centre.
Br J Dermatol
September 2025
Clinical Oncology, Guy's and Thomas' NHS Foundation Trust, London, uk.
Background: Primary Cutaneous CD4+ Small Medium T Cell Lymphoproliferative Disorder (PCSM-TLPD) is a rare subtype of indolent lymphoproliferative disease. The treatment, investigations and follow-up protocol are being re-evaluated.
Objective: To use our service evaluation to understand the presentation, response rate, relapse rate, treatment variation, progression free and overall survival of our cohort.
Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma.
Blood
September 2025
University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic, Hradec Králové, Czech Republic.
Epcoritamab is a subcutaneous CD3xCD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE® NHL-2 (phase 1b/2; NCT04663347). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years and R2 for up to 12 cycles (28 days/cycle).
View Article and Find Full Text PDFConcentration and integrity index of circulating cell-free DNA as a biomarker in pediatric patients with B-ALL.
Cell Mol Biol (Noisy-le-grand)
September 2025
Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Jalisco, México.
The objective of this study was to evaluate the concentration and integrity index of circulating cell-free DNA (ccf-DNA) as biomarkers for the detection and monitoring of minimal residual disease (MRD) in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Comparison with a validated methodology for the quantification of monoclonal rearrangements of the IGH gene was made. Peripheral blood and bone marrow samples were collected from 10 pediatric patients with B-ALL at diagnosis, remission, and maintenance phases.
View Article and Find Full Text PDFSymptoms, coronary artery disease and percutaneous coronary intervention: connecting the dots.
Curr Opin Cardiol
August 2025
National Heart and Lung Institute, Imperial College London.
Purpose Of Review: Symptom relief is now recognized as the primary remit of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease. The relationship between the nature of angina symptoms and the likelihood of successful symptom relief from PCI had not been systematically studied until recently.
Recent Findings: The ORBITA-2 symptom-stratified analysis found that while the severity and nature of symptoms were poorly associated with the severity of coronary disease, the nature of the symptoms powerfully predicted the efficacy of PCI in relieving angina.